| Item Type | Name |
|
Concept
|
Vomiting
|
|
Concept
|
Postoperative Nausea and Vomiting
|
|
Academic Article
|
Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis.
|
|
Academic Article
|
Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting.
|
|
Academic Article
|
Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
|
|
Academic Article
|
The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
|
|
Academic Article
|
Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.
|
|
Academic Article
|
Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. S3A-376 Study Group.
|
|
Academic Article
|
Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone.
|
|
Academic Article
|
Use of placebos in delayed-emesis studies.
|
|
Academic Article
|
Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
|
|
Academic Article
|
Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
|
|
Academic Article
|
Emerging drugs for chemotherapy-induced emesis.
|
|
Academic Article
|
Prevention of emesis from multiple-day and high-dose chemotherapy regimens.
|
|
Academic Article
|
Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and anti-nausea activities.
|
|
Academic Article
|
Inhibiting substance p pathway for prevention of chemotherapy-induced emesis: preclinical data, clinical trials of neurokinin-1 receptor antagonists.
|
|
Academic Article
|
Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.
|
|
Academic Article
|
A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study.
|
|
Academic Article
|
Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
|
|
Academic Article
|
Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial.
|
|
Academic Article
|
A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study.
|
|
Academic Article
|
Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist.
|
|
Academic Article
|
Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer.
|
|
Academic Article
|
Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group.
|
|
Academic Article
|
Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo.
|
|
Academic Article
|
Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin.
|
|
Academic Article
|
Antiemetic control: toward a new standard of care for emetogenic chemotherapy.
|
|
Academic Article
|
Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: approval and efficacy.
|
|
Academic Article
|
Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.
|
|
Academic Article
|
Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis: summary of clinical trials.
|
|
Academic Article
|
Ondansetron, prochlorperazine, and dexamethasone have similar effects on prevention of delayed chemotherapy-induced nausea and vomiting.
|
|
Academic Article
|
New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigations.
|
|
Academic Article
|
A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study.
|
|
Academic Article
|
Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
|
|
Academic Article
|
Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments.
|
|
Academic Article
|
The current status of the use of palonosetron.
|
|
Academic Article
|
Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents.
|
|
Academic Article
|
The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
|
|
Academic Article
|
Palonosetron for the treatment of chemotherapy-induced nausea and vomiting.
|
|
Academic Article
|
Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting.
|
|
Academic Article
|
Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV).
|
|
Academic Article
|
Clinical roundtable monograph: New data in emerging treatment options for chemotherapy-induced nausea and vomiting.
|
|
Academic Article
|
Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials.
|
|
Academic Article
|
5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy.
|
|
Academic Article
|
Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial.
|
|
Academic Article
|
Rolapitant for the treatment of chemotherapy-induced nausea and vomiting.
|
|
Academic Article
|
Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting.
|
|
Academic Article
|
Clinical trial data in chemotherapy-induced nausea and vomiting.
|
|
Academic Article
|
Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review.
|
|
Academic Article
|
The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting.
|
|
Academic Article
|
Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis.
|
|
Academic Article
|
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
|
|
Academic Article
|
Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting.
|
|
Academic Article
|
Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting.
|
|
Academic Article
|
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.
|
|
Academic Article
|
Rolapitant hydrochloride: prophylactic treatment for chemotherapy-induced nausea and vomiting.
|
|
Academic Article
|
2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.
|
|
Academic Article
|
Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy.
|
|
Academic Article
|
Olanzapine for Chemotherapy-Induced Nausea and Vomiting.
|
|
Academic Article
|
2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy.
|
|
Academic Article
|
Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients.
|
|
Academic Article
|
Managing Nausea and Vomiting in Patients With Cancer: What Works.
|
|
Academic Article
|
Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting.
|
|
Academic Article
|
Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations.
|
|
Academic Article
|
Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis.
|
|
Academic Article
|
Safety of Polysorbate 80 in the Oncology Setting.
|
|
Academic Article
|
Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy.
|
|
Academic Article
|
Thalidomide: Rebirth of a Gestational Antiemetic?
|
|
Academic Article
|
HTX-019: polysorbate 80- and synthetic surfactant-free neurokinin 1 receptor antagonist for chemotherapy-induced nausea and vomiting prophylaxis.
|
|
Academic Article
|
Do we still need to study palonosetron for chemotherapy-induced nausea and vomiting? A cumulative meta-analysis.
|
|
Academic Article
|
The safety of rolapitant for the treatment of nausea and vomiting associated with chemotherapy.
|
|
Academic Article
|
Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review.
|
|
Academic Article
|
Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy.
|
|
Academic Article
|
Impact of Addition of Carboplatin AUC = 4 to Antiemetic Guidelines for Triple Antiemetic Prophylaxis: A Gap in Quality of Care, Guideline Adoption, and Avoiding Acute Care.
|
|
Academic Article
|
Nausea and Vomiting in Advanced Cancer.
|
|
Academic Article
|
Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy.
|
|
Academic Article
|
Olanzapine for the Treatment of Advanced Cancer-Related Chronic Nausea and/or Vomiting: A Randomized Pilot Trial.
|
|
Academic Article
|
Olanzapine is an effective antiemetic agent.
|
|
Academic Article
|
What the HEC? Clinician Adherence to Evidence-Based Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy.
|
|
Academic Article
|
Unscheduled hydrations: redefining complete response in chemotherapy-induced nausea and vomiting studies.
|
|
Academic Article
|
The Importance of a Cause-Based Protocol to Approach Cancer-Related Nausea and Vomiting-Reply.
|
|
Academic Article
|
Efficacy of intravenous NEPA, a fixed NK1/5-HT3 receptor antagonist combination, for the prevention of chemotherapy-induced nausea and vomiting (CINV) during cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy: A review of phase 3 studies.
|
|
Academic Article
|
Avoidable Acute Care Use Associated with Nausea and Vomiting Among Patients Receiving Highly Emetogenic Chemotherapy or Oxaliplatin.
|
|
Academic Article
|
Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy (HEC) patients.
|
|
Academic Article
|
Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature.
|
|
Academic Article
|
Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis.
|
|
Academic Article
|
Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis.
|
|
Academic Article
|
Duration of Chemotherapy-Induced Nausea and Vomiting (CINV) as a Predictor of Recurrent CINV in Later Cycles.
|
|
Academic Article
|
Real-World Treatment Outcomes, Healthcare Resource Use, and Costs Associated with Antiemetics Among Cancer Patients on Cisplatin-Based Chemotherapy.
|
|
Academic Article
|
Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602).
|
|
Academic Article
|
Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
|
|
Academic Article
|
Work loss and activity impairment due to extended nausea and vomiting in patients with breast cancer receiving CINV prophylaxis.
|
|
Academic Article
|
2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.
|